Final Result of DIAL (NCI10089), Randomized Phase 2 trial of Varlilumab combined with Nivolumab in patients with relapsed/refractory aggressive B‐cell non‐Hodgkin lymphoma
Hematological Oncology | June 9, 2023 | Volume: 41 | Issue: S2 | Pages: 592-594
10.1002/hon.3164_444